Global Recombinant DNA Drug 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI08253516

Publication Date:

August 6, 2025

Pages:

139

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

According to this study, the global Recombinant DNA Drug market size will reach US$ 311339 million by 2031.
Recombinant DNA drugs are therapeutic agents produced using recombinant DNA technology, which involves inserting a gene encoding a therapeutic protein into a host cell (such as bacteria, yeast, or mammalian cells) to enable large-scale production of that protein. These drugs are typically biologics that mimic or supplement the function of naturally occurring substances in the body.
United States market for Recombinant DNA Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Recombinant DNA Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Recombinant DNA Drug is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Recombinant DNA Drug players cover Novo Nordisk, Amgen, Eli Lilly, Sanofi, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淩ecombinant DNA Drug Industry Forecast鈥� looks at past sales and reviews total world Recombinant DNA Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant DNA Drug sales for 2025 through 2031. With Recombinant DNA Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant DNA Drug industry.
This Insight Report provides a comprehensive analysis of the global Recombinant DNA Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Recombinant DNA Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Recombinant DNA Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant DNA Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant DNA Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant DNA Drug market by product type, application, key players and key regions and countries.
Segmentation by Type:
Fusion Protein
Recombinant Growth Factor
Recombinant Hormone
Recombinant Interferon
Recombinant Interleukin
Recombinant Coagulation Factor
Other
Segmentation by Application:
Cancers
Autoimmune Diseases
Metabolic Disorders
Infectious Diseases
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
Amgen
Eli Lilly
Sanofi
Bayer
Bristol-Myers Squibb
GlaxoSmithKline
AbbVie
Sandoz
Biogen
Pfizer
GenSci
3SBIO
Organon Pharma
Roche
Swedish Orphan Biovitrum
CSPC
Johnson & Johnson
Merck
Takeda

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Recombinant DNA Drug 麻豆原创 Size (2020-2031)
2.1.2 Recombinant DNA Drug 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Recombinant DNA Drug by Country/Region (2020, 2024 & 2031)
2.2 Recombinant DNA Drug Segment by Type
2.2.1 Fusion Protein
2.2.2 Recombinant Growth Factor
2.2.3 Recombinant Hormone
2.2.4 Recombinant Interferon
2.2.5 Recombinant Interleukin
2.2.6 Recombinant Coagulation Factor
2.2.7 Other
2.3 Recombinant DNA Drug 麻豆原创 Size by Type
2.3.1 Recombinant DNA Drug 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Recombinant DNA Drug 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Recombinant DNA Drug Segment by Application
2.4.1 Cancers
2.4.2 Autoimmune Diseases
2.4.3 Metabolic Disorders
2.4.4 Infectious Diseases
2.5 Recombinant DNA Drug 麻豆原创 Size by Application
2.5.1 Recombinant DNA Drug 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Recombinant DNA Drug 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Recombinant DNA Drug 麻豆原创 Size by Player
3.1 Recombinant DNA Drug 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Recombinant DNA Drug Revenue by Player (2020-2025)
3.1.2 Global Recombinant DNA Drug Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Recombinant DNA Drug Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Recombinant DNA Drug by Region
4.1 Recombinant DNA Drug 麻豆原创 Size by Region (2020-2025)
4.2 Global Recombinant DNA Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant DNA Drug 麻豆原创 Size Growth (2020-2025)
4.4 APAC Recombinant DNA Drug 麻豆原创 Size Growth (2020-2025)
4.5 Europe Recombinant DNA Drug 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Recombinant DNA Drug 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Recombinant DNA Drug 麻豆原创 Size by Country (2020-2025)
5.2 Americas Recombinant DNA Drug 麻豆原创 Size by Type (2020-2025)
5.3 Americas Recombinant DNA Drug 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant DNA Drug 麻豆原创 Size by Region (2020-2025)
6.2 APAC Recombinant DNA Drug 麻豆原创 Size by Type (2020-2025)
6.3 APAC Recombinant DNA Drug 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Recombinant DNA Drug 麻豆原创 Size by Country (2020-2025)
7.2 Europe Recombinant DNA Drug 麻豆原创 Size by Type (2020-2025)
7.3 Europe Recombinant DNA Drug 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant DNA Drug by Region (2020-2025)
8.2 Middle East & Africa Recombinant DNA Drug 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Recombinant DNA Drug 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Recombinant DNA Drug 麻豆原创 Forecast
10.1 Global Recombinant DNA Drug Forecast by Region (2026-2031)
10.1.1 Global Recombinant DNA Drug Forecast by Region (2026-2031)
10.1.2 Americas Recombinant DNA Drug Forecast
10.1.3 APAC Recombinant DNA Drug Forecast
10.1.4 Europe Recombinant DNA Drug Forecast
10.1.5 Middle East & Africa Recombinant DNA Drug Forecast
10.2 Americas Recombinant DNA Drug Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Recombinant DNA Drug Forecast
10.2.2 Canada 麻豆原创 Recombinant DNA Drug Forecast
10.2.3 Mexico 麻豆原创 Recombinant DNA Drug Forecast
10.2.4 Brazil 麻豆原创 Recombinant DNA Drug Forecast
10.3 APAC Recombinant DNA Drug Forecast by Region (2026-2031)
10.3.1 China Recombinant DNA Drug 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Recombinant DNA Drug Forecast
10.3.3 Korea 麻豆原创 Recombinant DNA Drug Forecast
10.3.4 Southeast Asia 麻豆原创 Recombinant DNA Drug Forecast
10.3.5 India 麻豆原创 Recombinant DNA Drug Forecast
10.3.6 Australia 麻豆原创 Recombinant DNA Drug Forecast
10.4 Europe Recombinant DNA Drug Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Recombinant DNA Drug Forecast
10.4.2 France 麻豆原创 Recombinant DNA Drug Forecast
10.4.3 UK 麻豆原创 Recombinant DNA Drug Forecast
10.4.4 Italy 麻豆原创 Recombinant DNA Drug Forecast
10.4.5 Russia 麻豆原创 Recombinant DNA Drug Forecast
10.5 Middle East & Africa Recombinant DNA Drug Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Recombinant DNA Drug Forecast
10.5.2 South Africa 麻豆原创 Recombinant DNA Drug Forecast
10.5.3 Israel 麻豆原创 Recombinant DNA Drug Forecast
10.5.4 Turkey 麻豆原创 Recombinant DNA Drug Forecast
10.6 Global Recombinant DNA Drug Forecast by Type (2026-2031)
10.7 Global Recombinant DNA Drug Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Recombinant DNA Drug Forecast
11 Key Players Analysis
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Recombinant DNA Drug Product Offered
11.1.3 Novo Nordisk Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Novo Nordisk Main Business Overview
11.1.5 Novo Nordisk Latest Developments
11.2 Amgen
11.2.1 Amgen Company Information
11.2.2 Amgen Recombinant DNA Drug Product Offered
11.2.3 Amgen Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Amgen Main Business Overview
11.2.5 Amgen Latest Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Company Information
11.3.2 Eli Lilly Recombinant DNA Drug Product Offered
11.3.3 Eli Lilly Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Eli Lilly Main Business Overview
11.3.5 Eli Lilly Latest Developments
11.4 Sanofi
11.4.1 Sanofi Company Information
11.4.2 Sanofi Recombinant DNA Drug Product Offered
11.4.3 Sanofi Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Sanofi Main Business Overview
11.4.5 Sanofi Latest Developments
11.5 Bayer
11.5.1 Bayer Company Information
11.5.2 Bayer Recombinant DNA Drug Product Offered
11.5.3 Bayer Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Bayer Main Business Overview
11.5.5 Bayer Latest Developments
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Information
11.6.2 Bristol-Myers Squibb Recombinant DNA Drug Product Offered
11.6.3 Bristol-Myers Squibb Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Bristol-Myers Squibb Main Business Overview
11.6.5 Bristol-Myers Squibb Latest Developments
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Information
11.7.2 GlaxoSmithKline Recombinant DNA Drug Product Offered
11.7.3 GlaxoSmithKline Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 GlaxoSmithKline Main Business Overview
11.7.5 GlaxoSmithKline Latest Developments
11.8 AbbVie
11.8.1 AbbVie Company Information
11.8.2 AbbVie Recombinant DNA Drug Product Offered
11.8.3 AbbVie Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 AbbVie Main Business Overview
11.8.5 AbbVie Latest Developments
11.9 Sandoz
11.9.1 Sandoz Company Information
11.9.2 Sandoz Recombinant DNA Drug Product Offered
11.9.3 Sandoz Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Sandoz Main Business Overview
11.9.5 Sandoz Latest Developments
11.10 Biogen
11.10.1 Biogen Company Information
11.10.2 Biogen Recombinant DNA Drug Product Offered
11.10.3 Biogen Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Biogen Main Business Overview
11.10.5 Biogen Latest Developments
11.11 Pfizer
11.11.1 Pfizer Company Information
11.11.2 Pfizer Recombinant DNA Drug Product Offered
11.11.3 Pfizer Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Pfizer Main Business Overview
11.11.5 Pfizer Latest Developments
11.12 GenSci
11.12.1 GenSci Company Information
11.12.2 GenSci Recombinant DNA Drug Product Offered
11.12.3 GenSci Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 GenSci Main Business Overview
11.12.5 GenSci Latest Developments
11.13 3SBIO
11.13.1 3SBIO Company Information
11.13.2 3SBIO Recombinant DNA Drug Product Offered
11.13.3 3SBIO Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 3SBIO Main Business Overview
11.13.5 3SBIO Latest Developments
11.14 Organon Pharma
11.14.1 Organon Pharma Company Information
11.14.2 Organon Pharma Recombinant DNA Drug Product Offered
11.14.3 Organon Pharma Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Organon Pharma Main Business Overview
11.14.5 Organon Pharma Latest Developments
11.15 Roche
11.15.1 Roche Company Information
11.15.2 Roche Recombinant DNA Drug Product Offered
11.15.3 Roche Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Roche Main Business Overview
11.15.5 Roche Latest Developments
11.16 Swedish Orphan Biovitrum
11.16.1 Swedish Orphan Biovitrum Company Information
11.16.2 Swedish Orphan Biovitrum Recombinant DNA Drug Product Offered
11.16.3 Swedish Orphan Biovitrum Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Swedish Orphan Biovitrum Main Business Overview
11.16.5 Swedish Orphan Biovitrum Latest Developments
11.17 CSPC
11.17.1 CSPC Company Information
11.17.2 CSPC Recombinant DNA Drug Product Offered
11.17.3 CSPC Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 CSPC Main Business Overview
11.17.5 CSPC Latest Developments
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Company Information
11.18.2 Johnson & Johnson Recombinant DNA Drug Product Offered
11.18.3 Johnson & Johnson Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Johnson & Johnson Main Business Overview
11.18.5 Johnson & Johnson Latest Developments
11.19 Merck
11.19.1 Merck Company Information
11.19.2 Merck Recombinant DNA Drug Product Offered
11.19.3 Merck Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Merck Main Business Overview
11.19.5 Merck Latest Developments
11.20 Takeda
11.20.1 Takeda Company Information
11.20.2 Takeda Recombinant DNA Drug Product Offered
11.20.3 Takeda Recombinant DNA Drug Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Takeda Main Business Overview
11.20.5 Takeda Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.